Adela, Inc.
Biotechnology
On its website, the company describes its work as “Best-in-class technology. Tissue-free detection. Adela is advancing the field of epigenomics to transform how cancer is detected and monitored. By leveraging proprietary methylome analysis technology…”.
Research Adela, Inc.
Tracking coverage
A source check is on hold. Previous evidence is retained.
- Momentum +1 · Limited coverage
- The latest public index does not report a rank for this company.Index checked:
- Fundraising +2 · Limited coverage
- Verified filings recorded. Existing baseline history earns no points.SEC source checked:
- New VC +3 · Awaiting data
- No verified dated source evidence recorded.
- Completed exit +10 · Source check held
- Latest source check was held; no new exit evidence was confirmed.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
What it does
On its website, the company describes its work as “Best-in-class technology. Tissue-free detection. Adela is advancing the field of epigenomics to transform how cancer is detected and monitored. By leveraging proprietary methylome analysis technology…”.
Tracked VC backing
No tracked VC backing recorded.
A portfolio listing documents backing; its observation date is not an investment date.
Dated public activity
· Form D filing · Baseline
Reported sold as filed: $12,000,000 · Offering amount as filed: $12,000,000
SEC source checked 29 Oct 2026. Historical filing, not a current valuation.
View original evidence ↗
History is research context. Only qualifying milestones after your pick earn points.